Prescription drug · ANDA
Tofacitinib Citrate NDC 68254-5012
Tofacitinib citrate 16.16 mg/1 · Tablet, Film coated · Oral · CONCORD BIOTECH LIMITED
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 68254-5012-1 | 6825450120168254501201 | 28 TABLET, FILM COATED in 1 BOTTLE (68254-5012-1)Marketed from Oct 1, 2026 | |
| 68254-5012-2 | 6825450120268254501202 | 60 TABLET, FILM COATED in 1 BOTTLE (68254-5012-2)Marketed from Oct 1, 2026 | |
| 68254-5012-3 | 6825450120368254501203 | 180 TABLET, FILM COATED in 1 BOTTLE (68254-5012-3)Marketed from Oct 1, 2026 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Tofacitinib Citrate
- Generic name (nonproprietary)
- tofacitinib citrate
- Active ingredients
- Tofacitinib citrate — 16.16 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- CONCORD BIOTECH LIMITEDNDC labeler code 68254
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 218821
- Marketing start
- Listing expires
- Other FDA classes
- Janus Kinase Inhibitors (Mechanism)
- Identifiers
- Product ID 68254-5012_ad6e5467-da25-405d-a725-c95489d79aabSPL ID ad6e5467-da25-405d-a725-c95489d79aabSPL set ID 6c33e5b4-4843-4a80-a4f8-435bfceddc2aRxCUI 1357541, 2048566UNII O1FF4DIV0D
- Pharmacologic class
- Janus Kinase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N468254501201followed by a unit qualifier and the quantityPackage 68254-5012-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Tofacitinib tablets are Janus kinase (JAK) inhibitors. Tofacitinib tablets are indicated for the treatment of adult patients with: Moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers. Active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. Active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers. Moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. Tofacitinib tablets are indicated for the treatment of pediatric pa…
Excerpt only. Read the full label for complete information.
About NDC 68254-5012
- What is NDC 68254-5012?
- 68254-5012 is the product NDC for Tofacitinib Citrate, Tofacitinib citrate 16.16 mg/1 tablet, film coated, listed with the FDA by CONCORD BIOTECH LIMITED. It has 3 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Tofacitinib Citrate.
- What is the active ingredient?
- Tofacitinib citrate.
- Who is the labeler?
- CONCORD BIOTECH LIMITED, NDC labeler code 68254. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Tofacitinib Citrate?
- 4 other product NDCs are listed under this name. See all Tofacitinib Citrate NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Tofacitinib Citrate products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Tofacitinib Citrate | Tofacitinib citrate 8.08 mg/1 | Tablet, Film coatedOral | Stellon Biotech Inc. | 85972-121 | 85972-0121-60 |
| Tofacitinib Citrate | Tofacitinib citrate 16.16 mg/1 | Tablet, Film coatedOral | Stellon Biotech Inc. | 85972-122 | 85972-0122-60 |
| Tofacitinib Citrate | Tofacitinib citrate 11 mg/1 | Tablet, Film coated, Extended releaseOral | ScieGen Pharmaceuticals, INC. | 50228-567 | 50228-0567-1050228-0567-30 |
| Tofacitinib Citrate | Tofacitinib citrate 11 mg/1 | Tablet, Film coated, Extended releaseOral | Radha Pharmaceuticals, Inc. | 77771-567 | 77771-0567-30 |
| Tofacitinib Citrate | Tofacitinib citrate 11 mg/1 | Tablet, Film coated, Extended releaseOral | Padagis US LLC | 0574-1811 | 00574-1811-30 |
Other NDCs under ANDA 218821
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Tofacitinib Citrate | Tofacitinib citrate 8.08 mg/1 | Tablet, Film coatedOral | Stellon Biotech Inc. | 85972-121 |
| Tofacitinib Citrate | Tofacitinib citrate 16.16 mg/1 | Tablet, Film coatedOral | Stellon Biotech Inc. | 85972-122 |